Key facts
- This page summarizes William Conkling's Form 4 filing for Rafael Holdings, Inc. (RFL).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Apr 2025, 15:18.
William Conkling - 25 Mar 2025 Form 4 Insider Report for Rafael Holdings, Inc. (RFL)
- Reporting relationship
- Chief Executive Officer
- Issuer ticker
- RFL
- Reported as of
- 25 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Apr 2025, 15:18:53 UTC
- Prior SEC filing
- 25 Mar 2025
- Next SEC filing
- 04 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- Joyce J. Mason, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William Conkling filed Form 4 for Rafael Holdings, Inc. (RFL) on 24 Apr 2025.
Change
- Previous filing in this sequence was filed on 25 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RFL
transaction
Class B Common Stock, par value $.01 per share
Award
- Transaction value
- Shares
- +27,454
- Change %
- +5.1%
- Price
- Shares after
- 564,455
- Date
- 25 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RFL
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- Shares
- +2,362
- Change %
- Price
- Shares after
- 2,362
- Date
- 25 Mar 2025
- Ownership
- Direct
- Underlying class
- Class B Common Stock
- Underlying amount
- 2,362
- Exercise price
- $3.89
- Footnotes
- F3
RFL
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- Shares
- +5,485
- Change %
- Price
- Shares after
- 5,485
- Date
- 25 Mar 2025
- Ownership
- Direct
- Underlying class
- Class B Common Stock
- Underlying amount
- 5,485
- Exercise price
- $3.63
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Reporting Person received these shares in exchange for 77,884 shares of Cyclo Therapeutics, Inc. ("Cyclo") common stock in connection with the business combination between Cyclo and the Issuer (the "Merger") based upon an exchange ratio of 0.3525.
Footnote F2
Consists of 174,409 shares of stock held directly, 183,094 fully vested shares of Restricted Stock and 206,952 shares of unvested Restricted Stock that vest as follows: 38,983 shares to vest quarterly, June 21, 2025 through September 21, 2025, and 38,986 shares to vest on December 21, 2025; 10,000 shares to vest on each of October 25, 2025, October 25, 2026 and October 25, 2027; and 15,000 shares to vest on each of January 13, 2026, January 13, 2027, January 13, 2028 and January 13, 2029.
Footnote F3
The Reporting Person received this option to purchase shares of stock in the Merger in exchange for an employee stock option granted to Mr. Conkling on June 6, 2023 to purchase 6,700 shares of Cyclo common stock at an exercise price of $1.37.
Footnote F4
The Reporting Person received this option to purchase shares of stock in the Merger in exchange for an employee stock option granted to Mr. Conkling on June 3, 2024 to purchase 15,562 shares of Cyclo common stock at an exercise price of $1.28.